

QMT1.1-CIP2-US

*U.S. Patent
Application 10/786,959
Response of February 28, 2006*

Claim Amendments

1-59. (canceled)

60. (currently amended): A method for treating skin ulcers, bed sores, or chronic wounds which comprises contacting said skin ulcers, bed sores, or chronic wounds with a substrate comprising a polyionic polymer bound to said substrate and a sufficient quantity of matrix metalloproteinase inhibitor ionically associated with said polyionic polymer to achieve extended release of said matrix metalloproteinase inhibitor onto and into said skin ulcer, bed sore or chronic wound to reduce or eliminate endogenous matrix metalloproteinase activity in said skin ulcer, bed sore or chronic wound.

61. (currently amended): A method of treating a wound which comprises contacting said wound with a substrate comprising a polyionic polymer bound to said substrate and a sufficient quantity of antibiotic, analgesic, anti-inflammatory, or a combination[[s]] thereof, ionically associated with said polyionic polymer to achieve extended release of said antibiotic, analgesic, anti-inflammatory, or combination[[s]] thereof onto and into said wound to reduce or eliminate microbial infection, pain, or inflammation at said wound site.

62. (canceled)

63. (new): The method of claim 60, wherein the polyionic polymer contains a multitude of quaternary amine groups.

64. (new): The method of claim 63, wherein the matrix metalloproteinase inhibitor is a carboxylic acid derivative of ilomastat.

65. (new): The method of claim 64, wherein the carboxylic acid derivative of ilomastat is GM 1489 or the C-terminal carboxylic acid form of ilomastat.

QMT1.1-CIP2-US

*U.S. Patent
Application 10/786,959
Response of February 28, 2006*

66. (new): The method of claim 60, wherein the polyionic polymer is a polymer of one or more allyl or vinyl monomers, containing quaternary ammonium groups.
67. (new): The method of claim 60, wherein the polyionic polymer is a polymer of diallyldimethylammonium chloride.
68. (new): The method of claim 60, wherein said substrate further comprises a hemostatic agent.
69. (new): The method of claim 61, wherein the polyionic polymer contains a multitude of quaternary amine groups.
70. (new): The method of claim 61, wherein the polyionic polymer is a polymer of one or more allyl or vinyl monomers, containing quaternary ammonium groups.
71. (new): The method of claim 61, wherein the polyionic polymer is a polymer of diallyldimethylammonium chloride.
72. (new): The method of claim 61, wherein said substrate further comprises a hemostatic agent.